Thursday 4 June 2015 4:30pm
CTCR researchers' innovation and expertise has attracted significant HRC funding for translational cancer research projects in the June 2015 funding round.
p53 in inflammatory disease and cancer
Professor Antony Braithwaite will investigate the complex role, and vulnerability, of p53 tumour suppressor protein in inflammatory disease and cancer. This programme has attracted $4.9m over five years.
Novel drug target in acute myeloid leukaemia
Associate Professor Julia Horsfield's project is studying a novel drug target in acute myeloid leukaemia with $1.1m over three years.
Trib1 pseudokinase in breast cancer pathology
Dr Peter Mace is investigating the signalling pathways of Trib1, a protein that is often over-expressed in breast cancer. This work attracted $1.1m over three years.
Chemoprevention and treatment of diffuse gastric cancer
Professor Parry Guilford's work in the chemoprevention and treatment of diffuse gastric cancer attracted $1.2m over three years. The research involves testing of potential new drugs on stomach 'organoids', the first time this technique has been used in New Zealand.
Read more about this project, and other funded studies in the Otago Daily Times:
- Otago researchers gain $32m in funding. 4 June, 2015, Otago Daily Times website